IN2015DN00538A - - Google Patents
Download PDFInfo
- Publication number
- IN2015DN00538A IN2015DN00538A IN538DEN2015A IN2015DN00538A IN 2015DN00538 A IN2015DN00538 A IN 2015DN00538A IN 538DEN2015 A IN538DEN2015 A IN 538DEN2015A IN 2015DN00538 A IN2015DN00538 A IN 2015DN00538A
- Authority
- IN
- India
- Prior art keywords
- uronamides
- alkynyladenosine
- ars
- disubstituted
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Nutrition Science (AREA)
Abstract
The present invention provides N-alkyl 2-(disubstituted)alkynyladenosine-5'-uronamides and derivatives thereof and pharmaceutical compositions containing the same that are selective agonists of A2A adenosine receptors (ARs). These compounds and compositions are useful as pharmaceutical agents.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261678605P | 2012-08-01 | 2012-08-01 | |
US201361787188P | 2013-03-15 | 2013-03-15 | |
PCT/US2013/053053 WO2014022577A1 (en) | 2012-08-01 | 2013-07-31 | N-alkyl 2-(disubstituted)alkynyladenosine-5-uronamides as a2a agonists |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2015DN00538A true IN2015DN00538A (en) | 2015-06-26 |
Family
ID=50025663
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN538DEN2015 IN2015DN00538A (en) | 2012-08-01 | 2013-07-31 |
Country Status (15)
Country | Link |
---|---|
US (1) | US9067963B2 (en) |
EP (1) | EP2879683B1 (en) |
JP (1) | JP6545618B2 (en) |
KR (1) | KR20150036767A (en) |
CN (1) | CN104582709A (en) |
AU (1) | AU2013296420B2 (en) |
BR (1) | BR112015002249A2 (en) |
CA (1) | CA2880040A1 (en) |
EA (1) | EA027174B1 (en) |
IL (1) | IL236986A (en) |
IN (1) | IN2015DN00538A (en) |
MX (1) | MX367879B (en) |
NZ (1) | NZ703992A (en) |
WO (1) | WO2014022577A1 (en) |
ZA (1) | ZA201501350B (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2325171B1 (en) | 2005-05-26 | 2013-10-09 | Aldexa Therapeutics, Inc. | Quinoline derivatives for treating retinal diseases |
US9822141B2 (en) * | 2012-08-01 | 2017-11-21 | Lewis And Clark Pharmaceuticals, Inc. | N-alkyl 2-(disubstituted)alkynyladenosine-5-uronamides as A2A agonists |
KR102435676B1 (en) | 2013-01-23 | 2022-08-24 | 알데이라 테라퓨틱스, 아이엔씨. | Toxic aldehyde related diseases and treatment |
WO2017035077A1 (en) | 2015-08-21 | 2017-03-02 | Aldeyra Therapeutics, Inc. | Deuterated compounds and uses thereof |
CA3022665A1 (en) | 2016-05-09 | 2017-11-16 | Aldeyra Therapeutics, Inc. | Combination treatment of ocular inflammatory disorders and diseases |
CA3054811A1 (en) | 2017-03-16 | 2018-09-20 | Aldeyra Therapeutics, Inc. | Polymorphic compounds and uses thereof |
CN111356451A (en) | 2017-10-10 | 2020-06-30 | 奥尔德拉医疗公司 | Treatment of inflammatory disorders |
WO2020033344A1 (en) | 2018-08-06 | 2020-02-13 | Aldeyra Therapeutics, Inc. | Polymorphic compounds and uses thereof |
CA3137301A1 (en) | 2019-05-02 | 2020-11-05 | Aldeyra Therapeutics, Inc. | Polymorphic compounds and uses thereof |
EP3988100A4 (en) * | 2019-06-21 | 2023-07-26 | Academy of Military Medical Sciences | Adenosine compound, pharmaceutically acceptable salt or stereoisomeride thereof, and use |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4559157A (en) | 1983-04-21 | 1985-12-17 | Creative Products Resource Associates, Ltd. | Cosmetic applicator useful for skin moisturizing |
LU84979A1 (en) | 1983-08-30 | 1985-04-24 | Oreal | COSMETIC OR PHARMACEUTICAL COMPOSITION IN AQUEOUS OR ANHYDROUS FORM WHOSE FATTY PHASE CONTAINS OLIGOMER POLYETHER AND NEW OLIGOMER POLYETHERS |
JPS6299395A (en) | 1985-10-25 | 1987-05-08 | Yamasa Shoyu Co Ltd | 2-alkinyladenosine and antihypertensive |
US4820508A (en) | 1987-06-23 | 1989-04-11 | Neutrogena Corporation | Skin protective composition |
US4992478A (en) | 1988-04-04 | 1991-02-12 | Warner-Lambert Company | Antiinflammatory skin moisturizing composition and method of preparing same |
US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
JPH02104783A (en) * | 1988-10-11 | 1990-04-17 | Kanai Hiroyuki | Steel cord and tire |
DE68916036T2 (en) | 1988-11-15 | 1994-09-29 | Toa Eiyo Ltd | AGENT FOR TREATMENT AND PROPHYLAXIS OF CORONARY AND CEREBRAL ISCHEMIC DISEASES. |
ATE127472T1 (en) | 1989-06-20 | 1995-09-15 | Yamasa Shoyu Kk | INTERMEDIATE COMPOUND FOR 2-ALKYNYLADENOSINE PRODUCTION, PRODUCTION OF THIS INTERMEDIATE COMPOUND, PRODUCTION OF 2-ALKYNYLADENOSINE FROM THIS INTERMEDIATE AND STABLE 2-ALKYNYLADENOSINE DERIVATIVE. |
US5189027A (en) | 1990-11-30 | 1993-02-23 | Yamasa Shoyu Kabushiki Kaisha | 2-substituted adenosine derivatives and pharmaceutical compositions for circulatory diseases |
JP3025557B2 (en) * | 1991-06-28 | 2000-03-27 | ヤマサ醤油株式会社 | 2-alkynyl adenosine derivatives |
IT1254915B (en) | 1992-04-24 | 1995-10-11 | Gloria Cristalli | ADENOSINE DERIVATIVES FOR ACTIVITY A2 AGONIST |
JP2002173427A (en) * | 1998-09-01 | 2002-06-21 | Yamasa Shoyu Co Ltd | Medicine composition for treating eye disease |
US6322771B1 (en) * | 1999-06-18 | 2001-11-27 | University Of Virginia Patent Foundation | Induction of pharmacological stress with adenosine receptor agonists |
CA2401832C (en) | 2000-03-23 | 2010-02-02 | Solvay Pharmaceuticals B.V. | 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity |
NZ556354A (en) | 2001-10-01 | 2008-10-31 | Univ Virginia | 2-Propynyl adenosine analogs having A2A agonist activity and compositions thereof |
DE60330250D1 (en) | 2002-09-09 | 2010-01-07 | Cv Therapeutics Inc | ADENOSINE A3 RECEPTOR AGONISTS |
EP1778712B1 (en) | 2004-08-02 | 2013-01-30 | University Of Virginia Patent Foundation | 2-propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity |
WO2006091896A2 (en) * | 2005-02-25 | 2006-08-31 | Adenosine Therapeutics, Llc | Pyridyl substituted xanthines |
WO2007120972A2 (en) * | 2006-02-10 | 2007-10-25 | University Of Virginia Patent Foundation | Method to treat sickle cell disease |
ATE500263T1 (en) * | 2006-06-27 | 2011-03-15 | Cbt Dev Ltd | NEW 2',3'-METHYLIDENACETYLADENOSINE PRODRUGS FOR USE AS ADENOSINE RECEPTOR AGONISTS |
US20080312160A1 (en) * | 2007-04-09 | 2008-12-18 | Guerrant Richard L | Method of treating enteritis, intestinal damage, and diarrhea from c. difficile with an a2a adenosine receptor agonist |
ES2537959T3 (en) | 2007-05-17 | 2015-06-16 | Gilead Sciences, Inc. | Process for preparing an adenosine-A2A receptor agonist and its polymorphs |
US8293720B2 (en) | 2007-12-20 | 2012-10-23 | Dogwood Pharmaceuticals, Inc. | Substituted 4-{3-[6-amino-9-(3, 4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists |
US8058259B2 (en) | 2007-12-20 | 2011-11-15 | University Of Virginia Patent Foundation | Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists |
AU2010266313A1 (en) | 2009-06-30 | 2012-01-19 | Forest Laboratories Holdings Limited | Alkoxy-carbonyl-amino-alkynyl-adenosine compounds and derivatives thereof as A2A R agonists |
-
2013
- 2013-07-31 AU AU2013296420A patent/AU2013296420B2/en not_active Ceased
- 2013-07-31 CA CA2880040A patent/CA2880040A1/en not_active Abandoned
- 2013-07-31 US US13/956,111 patent/US9067963B2/en not_active Expired - Fee Related
- 2013-07-31 MX MX2015001370A patent/MX367879B/en active IP Right Grant
- 2013-07-31 KR KR20157004901A patent/KR20150036767A/en not_active Application Discontinuation
- 2013-07-31 JP JP2015525562A patent/JP6545618B2/en not_active Expired - Fee Related
- 2013-07-31 IN IN538DEN2015 patent/IN2015DN00538A/en unknown
- 2013-07-31 NZ NZ703992A patent/NZ703992A/en not_active IP Right Cessation
- 2013-07-31 CN CN201380043401.9A patent/CN104582709A/en active Pending
- 2013-07-31 BR BR112015002249A patent/BR112015002249A2/en not_active Application Discontinuation
- 2013-07-31 EA EA201590205A patent/EA027174B1/en not_active IP Right Cessation
- 2013-07-31 EP EP13825985.8A patent/EP2879683B1/en active Active
- 2013-07-31 WO PCT/US2013/053053 patent/WO2014022577A1/en active Application Filing
-
2015
- 2015-01-29 IL IL236986A patent/IL236986A/en active IP Right Grant
- 2015-02-27 ZA ZA2015/01350A patent/ZA201501350B/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP2879683A1 (en) | 2015-06-10 |
EP2879683B1 (en) | 2020-01-22 |
US9067963B2 (en) | 2015-06-30 |
JP6545618B2 (en) | 2019-07-17 |
IL236986A (en) | 2017-06-29 |
MX2015001370A (en) | 2016-04-26 |
NZ703992A (en) | 2018-04-27 |
ZA201501350B (en) | 2016-12-21 |
JP2015524440A (en) | 2015-08-24 |
CN104582709A (en) | 2015-04-29 |
AU2013296420B2 (en) | 2017-12-07 |
CA2880040A1 (en) | 2014-02-06 |
EA201590205A1 (en) | 2015-06-30 |
MX367879B (en) | 2019-09-10 |
KR20150036767A (en) | 2015-04-07 |
EA027174B1 (en) | 2017-06-30 |
EP2879683A4 (en) | 2016-04-20 |
US20140037538A1 (en) | 2014-02-06 |
AU2013296420A1 (en) | 2015-02-12 |
WO2014022577A1 (en) | 2014-02-06 |
BR112015002249A2 (en) | 2017-07-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2015DN00538A (en) | ||
PH12019500522A1 (en) | Tetrahydropyrazolopyrimidine compounds | |
TN2017000357A1 (en) | Substituted nucleoside derivatives useful as anticancer agents | |
PH12016500642A1 (en) | Selective substituted quinoline compounds | |
MX2018006217A (en) | Apelin receptor agonists and methods of use. | |
MX2016004629A (en) | Selectively substituted quinoline compounds. | |
MD20170070A2 (en) | Quinazoline derivatives used to treat HIV | |
SG10201908839QA (en) | 2,4-dihydroxy-nicotinamides as apj agonists | |
CL2011003147A1 (en) | Compounds derived from n- (1-4- (1h-pyrazol-5-yl) phthalazine-1-yl) piperidine-4-yl) benzamide; pharmaceutical composition that contains them, useful as antagonist of the hedgehog trajectory, in the treatment of cancer. | |
MY191590A (en) | 9h-pyrrolo-dipyridine derivatives | |
MX2016015565A (en) | Certain protein kinase inhibitors. | |
GEP20186910B (en) | 1,2-substituted cyclopentanes as orexin receptor antagonists | |
MX2018015247A (en) | Biarylmethyl heterocycles. | |
BR112015012720A2 (en) | phenylethylpyridine derivatives as pde4 inhibitors | |
MX2017012783A (en) | Xanthine-substituted alkynyl carbamates/reverse carbamates as a2b antagonists. | |
PH12015502632A1 (en) | Cxcr7 receptor modulators | |
PH12018500504A1 (en) | Compounds useful for inhibiting ror-gamma-t | |
ZA202001780B (en) | Bezimidazole derivatives as adenosine receptor antagonists | |
IN2013MU00665A (en) | ||
MX2016015959A (en) | Carbamate derivatives which are both phosphodiesterase 4 (pde4) enzyme inhibitors and muscarinic m3 receptor antagonists. | |
MX2012000113A (en) | ALKOXY-CARBONYL-AMINO-ALKYNYL-ADENOSINE COMPOUNDS AND DERIVATIVES THEREOF AS A<sub>2A </sub>R AGONISTS. | |
UA111315C2 (en) | BENZIMIDAZOLONE DERIVATIVES AS BROMODOMEN INHIBITORS | |
LV14851A (en) | Triazolylpurine derivatives as agonists of adenosine and purine receptors | |
LV14852A (en) | Triazolylpurine derivatives as antiviral agents |